A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
- PMID: 26273440
- PMCID: PMC4527794
- DOI: 10.1002/ccr3.293
A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
Abstract
Lenalidomide is an immunomodulatory drug which is used to treat patients with MDS with deletion 5q chromosomal abnormality. In 2008, WHO introduced a new disease entity called MDS/MPN. No specific treatment for MDS/MPN subtype has yet been identified. We report a patient with MDS/MPN who responded well to lenalidomide therapy.
Keywords: 5q chromosomal abnormality; Lenalidomide; myelodysplastic syndrome; myelodysplastic syndrome/myeloproliferative neoplasm.
References
-
- Vardiman JW, Brunning RD, Arber DA. Le Beau MM, et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, editors; WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, WHO Classification of Tumours; 2008. pp. 18–30. Vol. 2.
-
- Foucar K. Myelodysplastic/myeloproliferative neoplasms. Am. J. Clin. Pathol. 2009;132:281–289. - PubMed
-
- Ermens AA, Vlasveld LT. Lindemens J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clin. Biochem. 2003;36:585–590. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
